Navigation Links
Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems
Date:1/24/2013

WASHINGTON and INGELHEIM, Germany, Jan. 24, 2013 /PRNewswire-USNewswire/ -- Boehringer Ingelheim and Ashoka Changemakers are launching Transforming Health Systems: Gamechanging Business Models, an online competition to discover innovative business models that are solving critical problems in health systems around the world.

"Traditional healthcare systems in mature markets are not designed to encourage enough collaboration between key players, such as care providers, insurance companies, and government organizations," said Jean Scheftsik de  Szolnok, Vice-President Southern Europe for Boehringer Ingelheim and Making More Health Steering Committee Chair. "Often, the systems' misaligned incentives fail to produce real value for patients and society. Innovative business models are urgently needed to solve this issue."

Transforming Health Systems also seeks business models that confront problems in emerging markets where governments, businesses, and non-profits often lack the resources or commitment to serve communities in need.

Winners will receive awards totaling US $85,000 plus support from Boehringer Ingelheim to help advance their business models. They will be matched with Boehringer Ingelheim's local country offices, and will be able to explore the potential for partnerships or further on-going support. All individuals, organizations, or partnerships are eligible to enter from now until April 10, 2013 at changemakers.com/healthbiz.

Transforming Health Systems was built on key insights gained from the first Making More Health competition launched by Boehringer Ingelheim and Ashoka Changemakers.

"The previous Making More Health competition added tremendously to Ashoka's network of social entrepreneurs who are working to solve the critical problems plaguing the world's health systems," said Ashoka President Diana Wells . "We have found that in tackling health from a systems level, most of our social entrepreneurs are finding ways to 1) deliver unlikely allies to solve the healthcare practitioner shortage  or 2) are innovating new delivery systems which can reach low income populations in both urban and rural areas.  We are excited to partner with Boehringer Ingelheim once again to tap the transformative power of social entrepreneurship and to solve one of the most critical issues that is confronting society today."

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing, and marketing novel products of high therapeutic value for human and veterinary medicine.

Social responsibility is a core element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of its global operations. Mutual cooperation and respect, as well as environmental protection and sustainability, are intrinsic values of all of Boehringer Ingelheim's endeavors.

For more information please visit www.boehringer-ingelheim.com

About Ashoka Changemakers

Ashoka Changemakers is a community of action that connects social entrepreneurs around the globe to share ideas, inspire, and mentor each other. Through its online collaborative competitions and open-source process, Changemakers.com is one of the world's most robust spaces for launching, discussing, and funding ideas to solve the world's most pressing social problems. Changemakers builds on Ashoka's three-decade history and belief that we all have the ability to be a Changemaker.

www.Changemakers.com

Media Contact:
Sonia Bianchi
Media Manager, Ashoka Changemakers
sbianchi@changemakers.com 
604.379.2292


'/>"/>
SOURCE Ashoka Changemakers
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... SAN FRANCISCO, Calif. , May 19, 2016 /PRNewswire/ ... a biopharmaceutical company developing novel therapeutics for the treatment ... announced that new GBT440 data will be presented in ... 21 st Congress in Copenhagen ... ongoing Phase 1/2 GBT440-001 study in sickle cell disease ...
(Date:5/19/2016)... 2016 BioLineRx Ltd. (NASDAQ/TASE: BLRX) ... treatment of multiple cancer and hematological indications, will be ... abstract titled " Clinical response in relapsed/refractory AML patients ... BL-8040, a potent CXCR4 antagonist; results of a Phase ... at the European Hematology Association 21st Congress, to be ...
(Date:5/19/2016)... CAMBRIDGE, Massachusetts , May 19, 2016 ... pharmaceuticals and diagnostics based on the gut microbiome, is pleased ... Cambridge, MA to support its operations ... office is located at Kendall Square, the heart of ... global hub for transforming scientific insights into new drugs. The ...
Breaking Medicine Technology:
(Date:5/24/2016)... Linda, CA (PRWEB) , ... May 24, 2016 ... ... fluorescent cell imaging; high content imaging; multiplex immunoassays are widely used for cell ... important for labs to maximize their quality and efficiency in these areas. , ...
(Date:5/23/2016)... ... 23, 2016 , ... On the occasion of his 25th Anniversary of changing ... loss process: , New patients have a consultation and evaluation (done by Dr. Ferdico ... , Body Composition Analysis, There are 15 things that each patient gets checked for, ...
(Date:5/23/2016)... ... 23, 2016 , ... According to an article published May 11th ... birth of her son, Rockwell Lloyd Liu, and notes that gestational surrogacy helped make ... Bill” star explains that, as a career oriented single woman, gestational surrogacy made parenthood ...
(Date:5/23/2016)... ... May 23, 2016 , ... NYDNRehab, a New York City-based ... athletes. This is the first time this type of technology, which was developed by ... to the public in New York. , With over 10 million sport injuries ...
(Date:5/23/2016)... ... May 23, 2016 , ... California State University Northridge ... quality of life and is currently focusing on ways to improve how people ... tested through research to find out whether watching them could have a significant ...
Breaking Medicine News(10 mins):